AzTrials
AzTrials

IVFNCT06191809

Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization

A study of IVF, run by Hanoi Medical University at 1 site in Vietnam.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study aims to evaluate the efficacy of the progestin-primed ovary stimulation (PPOS) protocol compared to the standard GnRH antagonist (GnRH_ant) protocol across successive stages in a controlled ovarian stimulation (COS) and ICSI procedure. Read more about this study

Who is it for?
Ages 20 to 45 years, women only
Conditions the study is for
IVF
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteVietnam
Study dates
14 Feb 2023to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Women meeting the sample selection criteria are as follows:
  • Women age 20 to 45 years old.
  • Infertility due to male factors, fallopian tube factors, or unknown causes.
  • Undergoing IVF in one COS cycle and intended to apply either GnRH antagonist protocol or PPOS protocol
  • Voluntary participation in research.

Who cannot join

  • Any contraindications to ovarian stimulation and IVF/ICSI treatment
  • Hyperprolactinemia or other endocrine diseases.
  • Those who took hormone drugs within the past 3 months
  • Suffering from systemic diseases such as kidney failure, lupus erythematosus, depression, etc.
  • Abnormal structure of the uterine cavity.
  • Patients with endometriosis or cancer
Show all 9Show fewer
  • Random-start cycles.
  • Oocyte donation cycles
  • Perform embryo biopsy.

Trial locations and contacts

1 site in 1 country.

Thach Than Trong contact

+84908400040

thachthan007@gmail.com

Khue Le Thai Thanh contact

+84975585249

lethaithanhkhue@gmail.com

Vietnam1 site, 1 recruiting
  • Univesity of Medicine and Pharmacy at Ho Chi Minh City

    Ho Chi Minh City, 700000

    Khue TT Le Thai Thanh, 0975585249, lethaithanhkhue@gmail.com

    Recruiting

Other trials in Vietnam

About this study

Official title: Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization: A Randomized Controlled Trial

This study aims to evaluate the efficacy of the progestin-primed ovary stimulation (PPOS) protocol compared to the standard GnRH antagonist (GnRH_ant) protocol across successive stages in a controlled ovarian stimulation (COS) and ICSI procedure.

Read the detailed description

Materials and Method

This was an open-label, randomized controlled trial conducted at the Assisted Reproduction Center of Tam Anh General Hospital. The study aimed to estimate the efficacy of the intervention (PPOS protocol) compared to a control group receiving a gonadotropin-releasing hormone (GnRH) antagonist protocol.

Sample size estimation

The sample size estimation procedure is detailed in the study protocol. In brief, the investigators conducted a simulation that implied the method by Cundill and Alexander (2015) with parameters derived from the clinical profile of 804 patients who underwent ovarian stimulation by two protocols at Tam Anh Hospital from January to October 2022. The procedure aimed to optimize non-inferiority testing on the difference in the quantity of retrieved oocytes between two groups, estimated by a Negative Binomial distribution. The simulation result indicated that a total sample size of 200 patients (n=100 for each treatment arm) would be required to achieve a statistical power of 0.8.

Recruitment of study participants

Infertile patients come for examination at the Assisted Reproduction Center of Tam Anh General Hospital, Hanoi, and the Assisted Reproduction and Graft Technology Center of Hanoi Medical University. In the basic infertility examination process at the hospital, the clinicians will consider the patient's inclusive and exclusive criteria. The clinicians will contact a research team member if the inclusive criteria are met. A research team member or hospital physician will invite the patient to participate, advise on the study procedure and the benefits and risks of participating, and answer any patient questions. If the patients agree to participate, they will consent to participate in the trial. Each participant will be randomly assigned to the treatment group using the PPOS protocol or the control group using the GnRH-ant regimen.

Treatment method

Ovarian stimulation protocols

Controlled ovarian hyperstimulation commenced on the second day of the menses utilizing recombinant follicle-stimulating hormone. In the gonadotropin-releasing hormone (GnRH) antagonist protocol group, pituitary suppression began on stimulation day six via daily 0.25 milligram GnRH antagonist administration (ganirelix or cetrorelix). In the progestin-primed ovarian stimulation (PPOS) group, 30mg/day of dydrogesterone was initiated on cycle day 2 through to trigger day.

Laboratory protocol

Oocyte-cumulus complexes were incubated for 2 hours in G-IVF medium (Vitrolife) using Origio benchtop incubators to complete nuclear maturation. After removing cumulus cells, denuded oocytes were evaluated under an inverted microscope to validate the achievement of metaphase II status, while degenerate, large, or severely dysmorphic oocytes were excluded. Intracytoplasmic sperm injection (ICSI) was executed 3-4 hours post-retrieval by experienced embryologists. Resultant zygotes were cultured in continuous single media (Fujifilm Irvine Scientific) within tri-gas incubators (37°C, 5% O2, 6% CO2) until day 3. Strict morphological criteria were enforced, only retaining normally fertilized two pronuclei zygotes while eliminating abnormal multinuclear embryos. Cleavage-stage quality was graded at 67-69 hours per Istanbul consensus based on cell number, fragmentation, multinucleation, and uniformity. On post-ICSI day 3, embryologists counseled patients on pursuing blastocyst culture versus cryopreservation. The morphology of the blastocysts was evaluated using the Gardner and Schoolcraft grading system, and embryos meeting the criteria of 3-6 AA/AB/BA blastocysts or 1-2 AA/AB embryos were classified as good quality.

Conditions
IVF
Being tested
Controlled Ovarian Stimulation Protocol
Keywords
ppos protocol

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Controlled Ovarian Stimulation ProtocolProcedure or surgery

    Ovarian Stimulation Process:

    • Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.
    • Monitor response with ultrasound \& hormones (E2, LH, P4).
    • GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.
    • PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.
    • Trigger ovulation when ≥2 follicles >17mm (Triptorelin, hCG, or rhCG).
    • Oocyte retrieval 36-38 hours later (>10mm follicles aspirated).

    Embryo Culture \& Monitoring:

    • Fertilize with ICSI.
    • Culture \& evaluate embryos (43-45 hours, day 3/5).
    • Freeze all embryos.
Study groups in NCT06191809
Study groupRoleWhat they receive
PPOS protocolActive comparatorOvarian stimulation protocol used progestin as premature LH surge inhibitor
Receives: Procedure: Controlled Ovarian Stimulation Protocol
GnRH-ant protocolActive comparatorOvarian stimulation protocol used GnRH antagonist as premature LH surge inhibitor
Receives: Procedure: Controlled Ovarian Stimulation Protocol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The quantity of day 3rd and day 5th embryos and MII oocytes

    Measured: 11 months after initiation of treatment in either arm

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2024
  2. Study start14 Feb 2023
  3. Primary completion31 Dec 2024 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06191809
Sponsor's protocol ID
9720105
Status last verified
Jan 2024
First submitted
16 Dec 2023
Last updated
5 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study of IVF, run by Hanoi Medical University at 1 site in Vietnam.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Thach Than Trong (+84908400040, thachthan007@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The quantity of day 3rd and day 5th embryos and MII oocytes (time frame: 11 months after initiation of treatment in either arm). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in